Robert H Andtbacka MD FACS, FRCSC
Melanoma, Surgical Oncology (Other than Breast)
Associate Professor, Surgery, University of Utah School of Medicine
Join to View Full Profile
50 N Medical DrSalt Lake City, UT 84132
Phone+1 801-581-2121
Fax+1 801-585-3749
Dr. Andtbacka is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
McGill University Faculty of MedicineClass of 1997
Certifications & Licensure
UT State Medical License 2006 - 2026
TX State Medical License 2003 - 2025
American Board of Surgery Surgery
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma Start of enrollment: 2009 Feb 01
- A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) Start of enrollment: 2011 Dec 29
- CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) Start of enrollment: 2012 Jul 03
Publications & Presentations
PubMed
- 7 citationsSociety for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.Jason J Luke, Diwakar Davar, Robert H Andtbacka, Nina Bhardwaj, Joshua D Brody
Journal for Immunotherapy of Cancer. 2024-04-18 - 5 citationsAgeing and endothelium-mediated vascular dysfunction: the role of the NADPH oxidases.Oh Sung Kwon, Sung Gi Noh, Soung Hun Park, Robert H I Andtbacka, John R Hyngstrom
The Journal of Physiology. 2023-02-01 - 13 citationsIntratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.Brendan D Curti, Jon Richards, John R Hyngstrom, Gregory A Daniels, Mark Faries
Journal for Immunotherapy of Cancer. 2022-12-01
Journal Articles
- Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT)Robert Andtbacka, MD, Annals of Oncology
Press Mentions
Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a Phase 2 Clinical Trial of the TLR 7/8 Dual Agonist BDB001 in Anti-PD-1 / Anti-PD-L1 Refractory Solid TumorsSeptember 7th, 2021- Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 Dual Agonist BDB018 in Advanced Solid TumorsJune 23rd, 2021
- Seven and Eight Biopharma’s BDB001 in Combination with Pembrolizumab Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 ASCO Annual MeetingJune 7th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
